Loading patent…
AssigneeWyeth
InventorsAndré Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
Estimating the term…
The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
A vaccine comprising an isolated nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID NO:15 and an acceptable pharmaceutical vehicle, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID NO:25 and SEQ ID NO:27.
An isolated immunogenic porcine circovirus Type B (PCVB) polypeptide having at least 90% identity to the sequence of SEQ ID NO:
A vaccine comprising an isolated nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID NO:15 and an acceptable pharmaceutical vehicle, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID NO:25 and SEQ ID NO:27.
A vaccine comprising an isolated nucleic acid having a nucleotide sequence with at least 95% sequence identity to SEQ ID NO:15 and an acceptable pharmaceutical vehicle, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID NO:25 and SEQ ID NO:27.
A vaccine comprising an isolated nucleic acid having a nucleotide sequence with at least 95% sequence identity to SEQ ID NO:15 and an acceptable pharmaceutical vehicle, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID NO:25 and SEQ ID NO:27.
An isolated immunogenic porcine circovirus Type B (PCVB) polypeptide having at least 95% identity to the sequence of SEQ ID NO:
A method for detecting PCVB homologous sequences in a biological sample comprising:
Dependencies are inferred from the claim text.